The overall objective of the ORBIS project is to improve the development of innovative and generic medicines. The way to achieve this goal is the cooperation of representatives of academic institutions from various fields of pharmaceutical sciences and the research and development sector of companies. Therefore, the core of the project is the international exchange of researchers between the consortium members and the project partner. The research includes the following stages of drug development: optimization of the synthesis of medicinal substances, preformulation studies, development of modern drug forms and their biopharmaceutical evaluation. The first employees of the company will start the first internship as part of this project in May this year.<\/p>\n\n\n\n
The leader of the project is the Karol Marcinkowski Medical University in Pozna\u0144 (UMP). Celon Pharma S.A. is a member of a consortium of scientific centers and enterprises from member states and associated with the European Union: Politechnika w Pradze (Czechy), Politechnika Pozna\u0144ska (Polska) Trinity College w Dublinie (Irlandia), Uniwersytet w Helsinkach (Finlandia), Uniwersytet w Lubljanie (S\u0142owenia), Applied Process Company Ltd. (Irlandia), Farmak JSC (Ukraina), Physiolution GmbH (Niemcy) i Zentiva k.s. (Czechy),. Partnerami projektu s\u0105 Rutgers -, The State University of New Jersey, USA oraz University of Central Florida, Orlando, USA.<\/p>\n\n\n\n
The project received funding from the European Commission in the Research and Innovation Staff Exchange (RISE) competition under the Marie Sk\u0142odowska-Curie Action of the Horizon 2020 Framework Programme (H2020-MSCA-RISE-2017), grant number 778051.<\/p>\n\n\n\n
Financing received by Celon Pharma: EUR 40 500<\/p>\n\n\n\n
Funding for all ORBIS project partners: EUR 2 268 000<\/p>\n\n\n\n
Website: https:\/\/orbisproject.eu\/<\/p>\n","protected":false},"excerpt":{"rendered":"